Edaravone and its clinical development for amyotrophic lateral sclerosis

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone

(2016) Akio Fujisawa et al.   REDOX REPORT

Gly482Ser PGC-1α Gene Polymorphism and Exercise-Related Oxidative Stress in Amyotrophic Lateral Sclerosis Patients

(2016) Angelique Pasquinelli et al.   Frontiers in Cellular Neuroscience

A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox

(2014) Erisa Kamogawa et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia

(2014) Yun Yuan et al.   BMC NEUROSCIENCE

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

(2014) Hiroshi Mitsumoto et al.   LANCET NEUROLOGY

Lack of Association between Nuclear Factor Erythroid-Derived 2-Like 2 Promoter Gene Polymorphisms and Oxidative Stress Biomarkers in Amyotrophic Lateral Sclerosis Patients

(2014) Annalisa LoGerfo et al.   Oxidative Medicine and Cellular Longevity

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

(2014) Koji Abe et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis

(2013) Emanuele D’Amico et al.   FREE RADICAL BIOLOGY AND MEDICINE

3-Nitrotyrosine: A biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions

(2013) Haseeb Ahsan   HUMAN IMMUNOLOGY

Redox Regulation in Amyotrophic Lateral Sclerosis

(2013) Sonam Parakh et al.   Oxidative Medicine and Cellular Longevity

Oxidative Stress Interferes With White Matter Renewal After Prolonged Cerebral Hypoperfusion in Mice

(2013) Nobukazu Miyamoto et al.   STROKE

The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease

(2010) Athan Baillet et al.   NEUROCHEMICAL RESEARCH

Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro

(2009) Brian J. Lee et al.   BRAIN RESEARCH

Oxidative stress biomarkers in sporadic ALS

(2008) Hiroshi Mitsumoto et al.   Amyotrophic Lateral Sclerosis

Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis

(2007) Takahiko Murata et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES